๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Primary Membranous Nephropathy
Clinical trial register · China

Primary Membranous Nephropathy Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 12 Guangzhou 9 Shenzhen 5 Shanghai 5 Jinan 3
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing12 Guangzhou9 Shenzhen5 Shanghai5 Jinan3
All 32 locations
Target enrolment
to

Primary Membranous Nephropathy trials in China

22 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
NCT07830433Primary Membranous Nephropathy
BioRay Pharmaceutical Co., Ltd.
Phase 3
150
Shanghai
2026-10
Not yet open
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
NCT07746453IgA Nephropathy (IgAN), Primary Membranous Nephropathy
Guangdong Provincial People's Hospital
Not applicable
24
Guangdong
2026-08-31
Not yet open
Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
NCT07730632IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G), Primary Membranous Nephropathy
Qilu Pharmaceutical Co., Ltd.
Phase 2
60
Beijing
2026-08-10
Not yet open
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy
NCT07765537Primary Membranous Nephropathy
DrugFKC289
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase 1/2
55
Hefei, Beijing, Guangzhou, Shenzhen, Wuhan, Changsha, Nanjing, Chengdu
2026-08
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan
2025-09-30
Recruiting
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT07157787Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.
Phase 2
30
Baotou, Beijing, Guangzhou, Shenzhen
2025-09-19
Recruiting
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
NCT07096843Primary Membranous Nephropathy
Climb Bio, Inc.
Phase 2
45
Beijing, Shenzhen, Wuxi, Xi'an, Jinan, Yantai, Yibin
2025-08-25
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
Biogen
Phase 3
180
Fuyang, Beijing, Xichengqu Beijing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Nanning
2025-05-22
Recruiting
Study of YK012 in Primary Membranous Nephropathy
NCT06982729Primary Membranous Nephropathy
DrugYK012
Excyte Biopharma Ltd
Phase 1
72
Beijing
2025-03-08
Active, closed
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
NCT06642909Primary Membranous Nephropathy
BioRay Pharmaceutical Co., Ltd.
Phase 2
135
Shanghai
2024-11-13
Recruiting
A Real World Study About PMN
NCT06893328Primary Membranous Nephropathy
Wei Chen
Observational
200
Guangzhou
2024-11-11
Recruiting
OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)
NCT06781944Primary Membranous Nephropathy
Huashan Hospital
Phase 3
144
Shanghai
2024-10-23
Not yet open
The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy
NCT06614985Primary Membranous Nephropathy
Renmin Hospital of Wuhan University
Phase 2
172
Wuhan
2024-10-20
Recruiting
Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy
NCT06573411Primary Membranous Nephropathy
First Affiliated Hospital, Sun Yat-Sen University
Phase 4
116
Guangzhou
2024-09-30
Recruiting
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
NCT06470191Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
216
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanning, Nantong, Qingdao
2024-07-30
Recruiting
Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy
NCT05514015Primary Membranous Nephropathy
First Affiliated Hospital, Sun Yat-Sen University
Phase 4
78
Guangzhou
2024-03-29
Active, closed
A Phase โ…ข Clinical Study of MIL62 in Primary Membranous Nephropathy
NCT05862233Primary Membranous Nephropathy
Beijing Mabworks Biotech Co., Ltd.
Phase 3
150
Beijing
2023-06-02
Active, closed
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
NCT05707377Primary Membranous Nephropathy
BeOne Medicines
Phase 2/3
178
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-04-17
Recruiting
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
NCT05668403Primary Membranous Nephropathy
DrugB007
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 1
52
Zhengzhou, Shijiazhuang, Hangzhou, Beijing, Shanghai
2023-03-02
Active, closed
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
NCT04629248Primary Membranous Nephropathy
Hoffmann-La Roche
Phase 3
142
Hangzhou, Beijing, Chengdu, Fuzhou, Guangzhou, Shanghai, Wuhan, Xi'an
2021-06-25
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/primary-membranous-nephropathy

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies listing the condition Primary Membranous Nephropathy.

How many Primary Membranous Nephropathy trials are recruiting in China?

12 of the 22 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Primary Membranous Nephropathy), 22 studies
PhaseStudiesRecruitingShare
Phase 26327.3%
Phase 35222.7%
Phase 2/33213.6%
Observational219.1%
Phase 1229.1%
Phase 4229.1%
Not applicable104.5%
Phase 1/2104.5%

Most active sponsors

Lead sponsors with the most studies (Primary Membranous Nephropathy)
Lead sponsorStudiesRecruiting
BioRay Pharmaceutical Co., Ltd.20
First Affiliated Hospital, Sun Yat-Sen University22
Shanghai Jiaolian Drug Research and Development Co., Ltd22
Alexion Pharmaceuticals, Inc.11
Beijing Mabworks Biotech Co., Ltd.10
BeOne Medicines10
Biogen11
Climb Bio, Inc.11
Excyte Biopharma Ltd11
Guangdong Hengrui Pharmaceutical Co., Ltd11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.